LuciPem — Pemigatinib 4.5 mg, 14 pcs, Lucius

LuciPem — Pemigatinib Tablets 4.5 mg, 14 Tablets

Product code: 511

18774₴ 20473₴ -8% On order · from 10 days

Analogues

LuciPem Pemitinib
1
Active ingredient
Dosage
4.5 mg
Dosage form Tablets
Tablets per pack 14

LuciPem is a highly selective targeted antineoplastic agent belonging to the fibroblast growth factor receptor (FGFR) inhibitor class, indicated for the treatment of cholangiocarcinoma (bile duct cancer) and other malignancies harboring FGFR gene aberrations. The active pharmaceutical ingredient is pemigatinib at a strength of 4.5 mg supplied as oral tablets (Pemigatinib Tablets 4.5 mg). The product is developed and manufactured by Lucius Pharmaceuticals.

Pemigatinib is a potent, oral, selective inhibitor of FGFR kinases (FGFR1, FGFR2, and FGFR3). Activating mutations, gene fusions, or amplifications of FGFR genes frequently occur in various solid tumors and drive uncontrolled cell proliferation, tumor survival, and angiogenesis. Selective suppression of FGFR activity by pemigatinib blocks these pathological signaling pathways, resulting in tumor cell apoptosis. The low 4.5 mg strength facilitates precise dosage titration and combination during cyclic dosing regimens.

Supplied in a package containing 14 tablets of 4.5 mg. Intended exclusively for oral administration under the strict supervision of an oncologist.

Key Clinical Features and Advantages of LuciPem 4.5 mg:

  • ✅ Selective FGFR1/2/3 Inhibition: Targeted blockade of fibroblast growth factor receptor kinases.
  • ✅ FGFR Mutation Therapy: High efficacy in patients with FGFR2 gene rearrangements and fusions (specifically in cholangiocarcinoma).
  • ✅ Proven Clinical Efficacy: Achievement of sustained responses in heavily pretreated patients with rare tumors.
  • ✅ Convenient Oral Dosing: Administered orally on specialized schedules (e.g., 2 weeks on / 1 week off).
  • ✅ Lucius Pharmaceuticals Standards: High-quality, accessible generic alternative to the originator product (Pemazyre).

LuciPem is supplied as tablets for oral administration.

Qualitative and Quantitative Composition per Tablet:

  • Active Ingredient: Pemigatinib — 4.5 mg.
  • Excipients: Microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, magnesium stearate, colloidal anhydrous silica. Coating/fillers: hypromellose, titanium dioxide, macrogol.

Packaging and Presentation: Tablets, 4.5 mg strength. Each package contains 14 tablets along with prescribing information. Labeled with LuciPem (Pemigatinib Tablets 4.5 mg) and Lucius Pharmaceuticals corporate graphics.

Pharmacodynamics:
Pemigatinib is a reversible, selective tyrosine kinase inhibitor of FGFR types 1, 2, and 3. It blocks FGFR phosphorylation and downstream signaling pathway activation, leading to the inhibition of tumor cell proliferation and induction of apoptosis in tissues characterized by abnormal FGFR signaling activation (such as FGFR2 fusions or mutations).

Pharmacokinetics:

  • Absorption: Following oral administration, pemigatinib is absorbed moderately fast; peak plasma concentration (Tmax) is achieved within approximately 1 to 2 hours. Food intake has no clinically significant effect on bioavailability.
  • Distribution: Human plasma protein binding is approximately 90.6%.
  • Metabolism: Metabolized in the liver primarily via cytochrome P450 enzymes (mainly CYP3A4) and aldehyde dehydrogenase.
  • Elimination: Excreted predominantly via feces (approx. 82% as metabolites and unchanged drug) and renally (approx. 12%). Terminal elimination half-life (T1/2) averages approximately 15.4 hours.

LuciPem is indicated in adult patients for:

  • Cholangiocarcinoma: Treatment of adult patients with locally advanced unresectable or metastatic cholangiocarcinoma with an FGFR2 gene fusion or rearrangement whose disease has progressed following at least one prior line of systemic therapy.

LuciPem is administered orally once daily.

Dosing Regimen:
The recommended standard dose is 13.5 mg once daily for the first 14 consecutive days followed by a 7-day off period (forming a 21-day treatment cycle). Treatment should continue until disease progression or unacceptable toxicity occurs.

Administration Guidelines:
Tablets should be taken at the same time each day, regardless of food intake, with water. Tablets must be swallowed whole; do not break, crush, or chew. If a dose is missed by more than 4 hours or if vomiting occurs after ingestion, skip that dose and take the next dose as scheduled.

Administration of LuciPem is contraindicated in:

  • Hypersensitivity: Known hypersensitivity to pemigatinib or any excipient (including lactose intolerance).
  • Pregnancy and Lactation: Strictly contraindicated in pregnant or breastfeeding women.
  • Pediatric Population: Safety and efficacy in patients under 18 years have not been established.
  • Severe Hepatic or Renal Impairment: Pronounced liver or kidney dysfunction (requiring caution or discontinuation).

Pemigatinib is metabolized primarily via CYP3A4:

  • Strong and Moderate CYP3A4 Inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit juice): May elevate pemigatinib plasma concentrations and toxicity risks (avoid concurrent use or reduce dose).
  • Strong and Moderate CYP3A4 Inducers (rifampicin, carbamazepine, phenytoin, St. John's Wort): Significantly decrease pemigatinib blood concentrations and reduce antitumor efficacy (avoid concurrent use).
  • Phosphate-Altering Agents: Since pemigatinib induces hyperphosphatemia, use caution with agents affecting phosphate balance.

Pregnancy:
LuciPem is contraindicated during pregnancy. Based on its mechanism of action, pemigatinib may cause fetal harm and embryotoxicity. Females of reproductive potential and male partners must utilize effective reliable contraception during treatment and for at least 1 month following the final dose.

Lactation:
Excretion of pemigatinib into human breast milk is unstudied. Breastfeeding must be discontinued during treatment and for 1 week post-therapy.

The most frequent and clinically significant adverse reactions include:

  • Laboratory Abnormalities: Hyperphosphatemia (a very common specific effect requiring blood phosphate monitoring and dietary management), elevated blood creatinine, increased liver transaminases.
  • Gastrointestinal Tract: Diarrhea, nausea, constipation, stomatitis, vomiting, abdominal pain, decreased appetite.
  • General Disorders: Fatigue, asthenia, peripheral edema, arthralgia, back pain.
  • Ocular Disorders: Dry eye, retinal pigment epithelial detachment (serous retinopathy), blurred vision (ophthalmic monitoring required).
  • Dermatologic Reactions: Alopecia, dry skin, rash, pruritus.

Symptoms:
Specific acute overdose symptoms of pemigatinib are unestablished. Anticipated manifestations include exacerbated adverse reactions (hyperphosphatemia, severe gastrointestinal disturbances, fatigue).

Treatment:
No specific antidote exists. In case of overdose, temporarily withhold treatment and initiate supportive and symptomatic care under electrolyte and patient status monitoring.

Storage Requirements for LuciPem 4.5 mg:

  • 🌡️ Temperature Range: Store in original packaging in a dry place protected from light at temperatures below 30 °C.
  • 👶 Safety Precautions: Keep strictly out of reach of children (cytotoxic antineoplastic agent).
  • ⏳ Shelf Life: Stated on carton and blister pack. Don't use past expiration date. Prescription-only oncology medicine.

To verify authenticity of genuine LuciPem 4.5 mg manufactured by Lucius Pharmaceuticals, inspect the following security and visual features:

  • ✅ Security Hologram & Scratch Code: Outer carton features an official Lucius Pharmaceuticals anti-counterfeit holographic seal with a scratch-off verification code for online validation via the manufacturer's official portal.
  • ✅ Corporate Branding: High-resolution printing displaying Lucius Pharmaceuticals graphics, Pemigatinib Tablets 4.5 mg, and 14 Tablets count.
  • ✅ Factory Markings: Clearly printed Batch No., Mfg. Date, and Exp. Date matching across outer packaging and internal blister packs.
  • ✅ Prescribing Information: Includes an official product leaflet inside the outer carton.
On order · from 10 days
100% original product
Delivery across Ukraine
1

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 17.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00